NCT04268784View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

February 20, 2020

Primary Completion Date

August 3, 2021

Study Completion Date

August 3, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

DNL343

Single and repeating oral dose(s)

DRUG

Placebo

Single and repeating oral dose(s)

Trial Locations (1)

2333

Centre for Human Drug Research (CHDR), Leiden

Sponsors
All Listed Sponsors
lead

Denali Therapeutics Inc.

INDUSTRY